Peer-influenced content. Sources you trust. No registration required. This is HCN.

Articles related to CLINICAL TRIALS

OBR Oncology

“Eye-Popping” Results From Adding Venetoclax to CLIA in Newly Diagnosed AML

Hematology January 23rd 2023

Blood

Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial

Hematology January 23rd 2023

The New England Journal of Medicine

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Oncology, Medical January 23rd 2023

The New England Journal of Medicine

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Hematology January 23rd 2023

Blood

Enasidenib vs. Conventional Care in Older Patients with Late-stage Mutant-IDH2 Relapsed/Refractory AML: A Randomized Phase 3 Trial

Hematology January 17th 2023

The New England Journal of Medicine

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Hematology January 17th 2023

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form